

Regenerative strategies in Cleft Palate

Subjects: Surgery

Contributor: Inês Francisco

Cleft lip and/or palate (CLP) is a craniofacial malformation with a prevalence in newborns of 14 per 10,000 live births worldwide.

Keywords: autogenous graft ; biomaterials

1. Introduction

Cleft lip and/or palate (CLP) is a craniofacial malformation with a prevalence in newborns of 14 per 10,000 live births worldwide ^[1]. Although not yet fully understood, several genetic and environmental risk factors are associated with CLP ^[2]. Smoking, gestational diabetes, and genetic association with the IRF6, VAX1, and PAX7 genes are consistently reported ^[3]^[4]. Most CLP patients have several hearing, feeding, speaking, and dentofacial development complications, leading to a long-term impact on the patient's facial anatomy and self-esteem ^[5]^[6].

One of the endpoints in CLP care is a secondary bone graft, which presents several benefits such as support of unerupted teeth that will erupt into the bone graft, support of alar bases (promoting nasal and lip symmetry), closure of oronasal fistulas and cleft maxillary segments stabilization ^[7]^[8]^[9]. The bone graft is usually performed when the canine has one-half to two-thirds root formed. Since its introduction by Boyne and Sands in 1972, autologous bone graft using cancellous bone remains the gold-standard until today ^[10]. Cancellous bone grafts have abundant osteogenic surface cells, which allow new bone formation ^[11]. The origin of the autogenous bone graft depends on numerous factors, namely, the surgeon's experience, the volume of alveolar defect, and the morbidity of the harvest area ^[12]. Typically, an autologous bone graft from the iliac crest (ICBG) is the conventional donor site ^[13]. However, others with less morbidity and lower bone resorption rate have been suggested, such as cranial bone, mandibular symphysis and tibia ^[14]^[15]^[16]. Nevertheless, autologous bone graft has several limitations, such as limited donor supply and/or self-renewal capacity, operative time, costs and donor site morbidity ^[17]. Furthermore, it is also reported that bone resorption can be approximately 40% after one year of bone graft, which may increase the need for reintervention ^[14].

Therefore, tissue regeneration presents as a new emerging and alternative approach to conventional bone grafts in cleft patients. Besides the bone regeneration capacity, these strategies can modulate inflammation and enhance the healing process ^[18]. Many substitute materials or agents alone or combined with autogenous bone have been suggested to regenerate bone, such as growth factors like bone morphogenetic protein 2 (BMP-2) platelet-rich fibrin, bone scaffolds with or without cell treatment (e.g., mesenchymal stem cells (MSCs) or osteoblast), biocomposites (e.g., calcium phosphate and hydroxyapatite) and haemostatic agents (e.g., fibrin glue) ^[12]^[19]^[20]^[21]^[22]^[23]^[24]^[25]. It must be pointed out that evidence regarding some of these therapeutic methods is often weak due to the lack of standardization across studies. To clarify this, we conducted an umbrella review to assess the clinical effectiveness of regenerative strategies on the treatment of secondary bone graft in cleft patients, which would be advantageous for readership since it synthesizes what we know in a single paper. Therefore, this umbrella review aims to answer the following focused question: "Is the regenerative capacity of new bone graft strategies more effective than the gold-standard?"

2. Study Selection

The flow chart for this umbrella review can be seen in [Figure 1](#). The search in the different databases resulted in 1317 articles, with no paper retrieved from grey literature or from the manual search. After the articles were screened by title and abstract, 20 full-text articles were assessed for eligibility. Full-text screening led to the exclusion of 11 articles due to several reasons: one case-report, two literature reviews, four with different interventions or outcomes, four with other measures of bone regeneration and one poster abstract. Nine systematic reviews were included in the qualitative analysis and five in the quantitative analysis (meta-analysis).




Figure 1. Flow chart for included systematic reviews.

3. Synthesis of the Best Evidence

The quality of the included reviews evaluated by the AMSTAR2 tool, four reviews were considered to be of low quality [16,41,44,45], four were considered to be of moderate quality [24,42,46,47] and one was considered to be of high quality [43].

3.1. Bone Formation Volume Analysis

The quantitative analysis of previous meta-analysis synthetic measures was possible using three systematic reviews (Rosa et al., 2019, Uribe et al., 2019 and Xiao et al., 2020) [26][27][28] and showed no heterogeneity between previous synthetic measures ($I^2 = 0.00\%$). Besides this, the random effects model was still applied due to the number of studies in the analysis, and we found that the global standardized mean difference between ICBG and BMP-2 was not statistically significant ($p = 0.704$) and was estimated to be $0.08 \text{ mm}^3 \pm 0.22 \text{ mm}^3$ (95% CI: -0.35 to 0.51 mm^3), as presented in Figure 1.




Figure 1. Forest plot for the standardized mean difference obtained for bone formation volume analysis synthetic measures reported in the included systematic reviews.

3.2. Bone Formation Percentage Analysis

The quantitative analysis of previous meta-analysis synthetic measures was possible considering four systematic reviews (Rosa et al., 2019, Wu et al., 2017, Xiao et al., 2020 and Uribe et al., 2019) [26][29][27][28] and showed high heterogeneity between studies ($I^2 = 93.8\%$), perhaps due to Wu et al., 2017 [29], which is the only one presenting a statistically

significant effect. Despite this, a global standardized mean difference between ICBG and BMP-2 was estimated and found not to be statistically significant ($p = 0.184$) and was estimated to be $67.92\% \pm 51.05\%$ (95% CI: -32.13 to 167.97%), as presented in [Figure 2](#).




Figure 2. Forest plot for the standardized mean difference obtained for bone formation percentage analysis synthetic measures reported in the included systematic reviews.

3.3. Bone Height

The quantitative analysis of bone height was possible with three systematic reviews (Uribe et al., 2019, Xiao et al., 2020 and Scalzone et al., 2019) ^{[26][30][28]} and heterogeneity between studies was found to be almost the maximum ($I^2 = 99.88\%$), as Xiao et al., 2020 ^[26] presented a large statistically significant effect when compared to the others. Despite this, a global standardized mean difference between ICBG and BMP-2 was estimated and found not to be statistically significant ($p = 0.520$) and was estimated to be $5.13\% \pm 9.97\%$ (95% CI: -10.49 to 20.74%), as presented in [Figure 3](#).




Figure 3. Forest plot for the standardized mean difference obtained for bone height synthetic measures reported in the included systematic reviews.

4. Quality of the Evidence

4.1. Bone Formation Volume Analysis

The effect size reported by the studies used in the previous meta-analysis did not depend on the precision of the studies (Egger regression $b = 0.04$; $p = 0.931$), and was not correlated to the studies variance (Begg–Mazumdar: $t_{Kendal} = 0.333$; $p = 0.999$) indicating lack of publication bias concerning the influence of sample size and variability on the mean difference between treatments.

4.2. Bone Formation Percentage Analysis

The effect size reported by the studies used in the previous meta-analysis did not depend on the precision of the studies (Egger regression $b = -0.08$; $p = 0.939$), and was not correlated to its variance (Begg–Mazumdar test: $t_{Kendal} = 0.000$; $p = 1.000$).

4.3. Bone Height

The effect size reported by the studies used in the previous meta-analysis did not depend on the precision of the studies (Egger regression $b = -4.17$; $p = 0.485$), and was not related to the variance of the effects reported (Begg–Mazumdar test: $t_{\text{Kendal}} = 0.333$; $p = 0.999$), indicating lack of publication bias.

5. Discussion

This umbrella review aimed to synthesize the current literature regarding bone strategies in cleft patients, evaluating their success or failure based on systematic reviews with/without meta-analyses.

Conventionally, an autologous bone graft using cancellous bone is considered the gold-standard technique for bone graft [10]. All included studies that had a comparator group used autologous bone graft as a control. The effectiveness of tissue regeneration approaches was also investigated, with human bone morphogenetic protein being the most reported in 6 of the 9 systematic reviews included. BMP-2 is usually delivered in an alloplastic bone graft or scaffold and is an effective inducer of bone and cartilage formation, belonging to the transforming growth factor-beta proteins superfamily. This protocol avoids the limitations of autologous bone grafts, such as limited donor supply and donor site morbidity, and reduces the patient's surgical stress, which may be related to the lower operative time and hospital stay length, reported by some studies [31][32]. However, some adverse effects such as nasal stenosis and localized graft-site oedema still persist [26][30][33].

Although some of the systematic reviews included indicated that BMP-2 treatment may benefit bone formation compared to autogenous bone graft, this umbrella review reported no significant difference between these two protocols regarding volume, filling, and bone height [30][28]. However, these findings should be interpreted with caution because clinical and methodological heterogeneity can influence the magnitude of the statistical heterogeneity reported. This umbrella review identified different heterogeneity factors, namely, the number of participants, type of cleft, the timing of outcome, and intervention design. Thus, the results of the included studies can be affected by this heterogeneity, and, consequently, the results of this umbrella review can also be affected. Additionally, some SR results could not be used for the meta-analysis due to different synthesis measures, decreasing the number of included studies, which can affect the obtained result. Nevertheless, the quality assessment revealed that only one study included has a high risk of bias, which gives more confidence in the results of this umbrella review. Therefore, both methods can be an option in cleft bone graft treatment.

The timing for the bone graft is a variable that clinicians should consider because it can influence the bone graft prognosis, endangering the support provided for teeth eruption, the continuity of dental arch and the closure of the oronasal fistula [33]. Despite the difference in the selected studies' age groups, the majority performed the bone graft after 8 years of age, which is by the ideal timing reported in the literature [34][35][36]. Furthermore, a recent study by Brudnicki et al. reported that bone grafts performed before 8 years old might have a limited negative effect on craniofacial morphology [33]. Regarding the postoperative newly formed bone evaluation, most included studies used computed tomography. The orofacial cleft patients require a 3D analysis for the correct diagnosis since they present with several medical conditions, namely bone graft interventions, impacted teeth or supernumerary teeth. This is the reason why CBCT is indicated in orofacial cleft patients by the European Academy of Dental and Maxillofacial Radiology [37]. Therefore, further studies should use CBCT as an assessment tool to measure newly formed bone.

Follow-up times are not consensual, even though most of the trials included in the systematic review reported a follow-up of six months. This period is ideal for carrying out radiograph control since the remodeling process with cortical maturation occurs after six months, remaining stable until the 24th month. Regarding the included studies, only Scalzone et al. considered trials with at least six months of follow-up [30]. The remaining systematic reviews' findings should be carefully analyzed since the remodeling process may not be completed.

The findings of this umbrella review could be affected by the methodological and clinical heterogeneity among the included studies. Most of the included studies failed to discuss the heterogeneity and the risk of bias, especially in justifying the inclusion of studies with different methodologies and the consequent bias. Therefore, their conclusions must be interpreted with caution. Several SRs included in this umbrella review presented some gaps in the search description and inclusion criteria definition, which potentially increase the risk of publication and reduce the comprehensive nature of the review. Thus, the registration of the protocol is recommended and will enhance the robustness in further research. The methodological heterogeneity includes differences in the trial settings, missing a priori adequate sample size calculation, type of sample included (e.g., type of cleft, age groups), intervention protocols, bone measurement tools and follow-up times.

Future research should carry out blinded RCTs to control possible sources of bias such as randomization procedure, measurement tools and follow-up times. Moreover, the cost-benefit analysis of these new regenerative strategies in the bone graft is recommended since it plays a crucial role in healthcare systems' decision-making.

6. Conclusions

This umbrella review suggests that BMP-2 and autogenous bone graft are both valid options since no differences were observed regarding volume, filling, and bone height in oral cleft patients' surgery.

However, the findings should be analyzed cautiously due to several research gaps concerning the original studies' methodological quality.

References

1. Vieira, A.R.; Orioli, I.M. Birth order and oral clefts: A meta analysis. *Teratology* 2002, 66, 209–216.
2. Dixon, M.J.; Marazita, M.L.; Beaty, T.H.; Murray, J.C. Cleft lip and palate: Understanding genetic and environmental influences. *Nat. Rev. Genet.* 2011, 12, 167–178.
3. Leslie, E.J.; Marazita, M.L. Genetics of cleft lip and cleft palate. *Am. J. Med. Genet. Part C Semin. Med. Genet.* 2013, 163, 246–258.
4. Zhang, L.; Wang, X.-H.; Zheng, X.-M.; Liu, T.-Z.; Zhang, W.-B.; Zheng, H.; Chen, M.-F. Maternal Gestational Smoking, Diabetes, Alcohol Drinking, Pre-Pregnancy Obesity and the Risk of Cryptorchidism: A Systematic Review and Meta-Analysis of Observational Studies. *PLoS ONE* 2015, 10, e0119006.
5. Kohli, S.; Kohli, V. A comprehensive review of the genetic basis of cleft lip and palate. *J. Oral Maxillofac. Pathol.* 2012, 16, 64.
6. Sa, J.; Araujo, L.; Guimaraes, L.; Maranhao, S.; Lopes, G.; Medrado, A.; Coletta, R.; Reis, S. Dental anomalies inside the cleft region in individuals with nonsyndromic cleft lip with or without cleft palate. *Med. Oral Patol. Oral y Cir. Bucal* 2016, 21, e48–e52.
7. Graber, T.; Vanarsdall, R.V.K. *Orthodontics Current Principles & Techniques*, 4th ed.; Elsevier Mosby: St. Louis, MO, USA, 2005.
8. Kuijpers-Jagtman, A.M. The orthodontist, an essential partner in CLP treatment. *PubMed* 2006, 4, 57–62.
9. Bittermann, G.K.P.; van Es, R.J.J.; de Ruiter, A.P.; Bittermann, A.J.N.; Koole, R.; Rosenberg, A.J.W.P. Retrospective analysis of clinical outcomes in bilateral cleft lip and palate patients after secondary alveolar bone grafting and premaxilla osteotomy, using a new dento-maxillary scoring system. *J. Cranio-Maxillofac. Surg.* 2021, 49, 110–117.
10. Boyne, P.J.; Sands, N.R. Secondary bone grafting of residual alveolar and palatal clefts. *J. Oral Surg.* 1972, 30, 87–92.
11. Åbyholm, F.E.; Bergland, O.; Semb, G. Secondary Bone Grafting of Alveolar Clefts: A Surgical/Orthodontic Treatment Enabling a Non-prosthetic Rehabilitation in Cleft Lip and Palate Patients. *Scand. J. Plast. Reconstr. Surg.* 1981, 15, 127–140.
12. Khojasteh, A.; Kheiri, L.; Motamedian, S.R.; Nadjmi, N. Regenerative medicine in the treatment of alveolar cleft defect: A systematic review of the literature. *J. Cranio-Maxillofac. Surg.* 2015, 43, 1608–1613.
13. Erica Alexandra, M.P.; Andre, B.; Priscila, L.C.; Patricia, N.T. Alveolar Bone Graft: Clinical Profile and Risk Factors for Complications in Oral Cleft Patients. *Cleft Palate-Craniofacial J.* 2017, 54, 530–534.
14. Rawashdeh, M.A.; Telfah, H. Secondary Alveolar Bone Grafting: The Dilemma of Donor Site Selection and Morbidity. *Br. J. Oral Maxillofac. Surg.* 2008, 46, 665–670.
15. Shirzadeh, A.; Rahpeyma, A.; Khajehahmadi, S. A Prospective Study of Chin Bone Graft Harvesting for Unilateral Maxillary Alveolar Cleft During Mixed Dentition. *J. Oral Maxillofac. Surg.* 2018, 76, 180–188.
16. Kilinc, A.; Saruhan, N.; Ertas, U.; Korkmaz, I.H.; Kaymaz, I. An Analysis of Mandibular Symphyseal Graft Sufficiency for Alveolar Cleft Bone Grafting. *J. Craniofac. Surg.* 2017, 28, 147–150.
17. Brudnicki, A.; Rachwalski, M.; Wiepszowski, Ł.; Sawicka, E. Secondary alveolar bone grafting in cleft lip and palate: A comparative analysis of donor site morbidity in different age groups. *J. Cranio-Maxillofac. Surg.* 2019, 47, 165–169.
18. Zumarán, C.; Parra, M.; Olate, S.; Fernández, E.; Muñoz, F.; Haidar, Z. The 3 R's for Platelet-Rich Fibrin: A “Super” Tri-Dimensional Biomaterial for Contemporary Naturally-Guided Oro-Maxillo-Facial Soft and Hard Tissue Repair, Reconstruction and Regeneration. *Materials* 2018, 11, 1293.

19. Francisco, I.; Fernandes, M.H.; Vale, F. Platelet-Rich Fibrin in Bone Regenerative Strategies in Orthodontics: A Systematic Review. *Materials* 2020, 13, 1866.
20. Kamal, M.; Ziyab, A.H.; Bartella, A.; Mitchell, D.; Al-Asfour, A.; Hölzle, F.; Kessler, P.; Lethaus, B. Volumetric comparison of autogenous bone and tissue-engineered bone replacement materials in alveolar cleft repair: A systematic review and meta-analysis. *Br. J. Oral Maxillofac. Surg.* 2018, 56, 453–462.
21. Al-Ahmad, H.H.; Abd Elazeem, A.F.; Ahmed, N.E.; Shawkat, W.M.; Elmasry, M.; Abdelrahman, M.A.; Abderazik, M.A. Combining autologous bone marrow mononuclear cells seeded on collagen sponge with Nano Hydroxyapatite, and platelet-rich fibrin: Reporting a novel strategy for alveolar cleft bone regeneration. *J. Cranio-Maxillofac. Surg.* 2018, 46, 1593–1600.
22. Huang, L.; Zou, R.; He, J.; Ouyang, K.; Piao, Z. Comparing osteogenic effects between concentrated growth factors and the acellular dermal matrix. *Braz. Oral Res.* 2018, 32, e29.
23. Du, F.; Wu, H.; Li, H.; Cai, L.; Wang, Q.; Liu, X.; Xiao, R.; Yin, N.; Cao, Y. Bone Marrow Mononuclear Cells Combined with Beta-Tricalcium Phosphate Granules for Alveolar Cleft Repair: A 12-Month Clinical Study. *Sci. Rep.* 2017, 7, 13773.
24. Miyagawa, K.; Tanaka, S.; Hiroishi, S.; Matsushita, Y.; Murakami, S.; Kogo, M. Comparative evaluation of bone microstructure in alveolar cleft repair by cone beam CT: Influence of different autologous donor sites and additional application of β -tricalcium phosphate. *Clin. Oral Investig.* 2020, 24, 2789–2797.
25. Sakamoto, Y.; Sakamoto, T.; Ishii, T.; Kishi, K. Assessment of Bioabsorbable Hydroxyapatite for Secondary Bone Grafting in Unilateral Alveolar Clefts. *Cleft Palate-Craniofacial J.* 2020, 57, 114–117.
26. Xiao, W.; Jia, K.; Yu, G.; Zhao, N. Outcomes of bone morphogenetic protein-2 and iliac cancellous bone transplantation on alveolar cleft bone grafting: A meta-analysis. *J. Plast. Reconstr. Aesthetic Surg.* 2020, 73, 1135–1142.
27. da Rosa, W.L.; da Silva, T.M.; Galarça, A.D.; Piva, E.; da Silva, A.F. Efficacy of rhBMP-2 in Cleft Lip and Palate Defects: Systematic Review and Meta-analysis. *Calcif. Tissue Int.* 2019, 104, 115–129.
28. Uribe, F.; Alister, J.P.; Zaror, C.; Olate, S.; Fariña, R. Alveolar Cleft Reconstruction Using Morphogenetic Protein (rhBMP-2): A Systematic Review and Meta-Analysis. *Cleft Palate-Craniofacial J.* 2020, 57, 589–598.
29. Wu, C.; Pan, W.; Feng, C.; Su, Z.; Duan, Z.; Zheng, Q.; Hua, C.; Li, C. Grafting materials for alveolar cleft reconstruction: A systematic review and best-evidence synthesis. *Int. J. Oral Maxillofac. Surg.* 2018, 47, 345–356.
30. Scalzone, A.; Flores-Mir, C.; Carozza, D.; D'Apuzzo, F.; Grassia, V.; Perillo, L. Secondary alveolar bone grafting using autologous versus alloplastic material in the treatment of cleft lip and palate patients: Systematic review and meta-analysis. *Prog. Orthod.* 2019, 20, 6.
31. Mehta, S.; Blagg, R.; Willcockson, J.; Gociman, B.; Yamashiro, D.; Siddiqi, F. Cost-Effectiveness Analysis of Demineralized Bone Matrix and rhBMP-2 versus Autologous Iliac Crest Bone Grafting in Alveolar Cleft Patients. *Plast. Reconstr. Surg.* 2018, 142, 737–743.
32. Trujillo, R.L.; Kadioglu, O.; Currier, G.F.; Smith, K.S.; Yetkiner, E. Volumetric Cleft Changes in Treatment With Bone Morphogenetic Protein/ β -Tricalcium Phosphate Versus Grafts From the Iliac Crest or Symphysis. *J. Oral Maxillofac. Surg.* 2018, 76, 1991–1997.
33. Brudnicki, A.; Sawicka, E.; Brudnicka, R.; Fudalej, P.S. Effects of Different Timing of Alveolar Bone Graft on Craniofacial Morphology in Unilateral Cleft Lip and Palate. *Cleft Palate-Craniofacial J.* 2020, 57, 105–113.
34. Pinheiro, F.H.; Drummond, R.J.; Frota, C.M.; Bartzela, T.N.; Santos, P.B. Comparison of early and conventional autogenous secondary alveolar bone graft in children with cleft lip and palate: A systematic review. *Orthod. Craniofac. Res.* 2020, 23, 385–397.
35. Siegenthaler, M.; Bettelini, L.; Brudnicki, A.; Rachwalski, M.; Fudalej, P.S. Early versus late alveolar bone grafting in unilateral cleft lip and palate: Dental arch relationships in pre-adolescent patients. *J. Cranio-Maxillofac. Surg.* 2018, 46, 2052–2057.
36. Fahradyan, A.; Tsuha, M.; Wolfswinkel, E.M.; Mitchell, K.-A.S.; Hammoudeh, J.A.; Magee, W. Optimal Timing of Secondary Alveolar Bone Grafting: A Literature Review. *J. Oral Maxillofac. Surg.* 2019, 77, 843–849.
37. European Commission. Radiation protection No 172. Cone Beam CT for Dental and Maxillofacial Radiology. Evidence Based Guidelines; European Commission: Luxembourg, 2012.

